Mezzion Pharma Acquires Additional Shares in U.S. Subsidiary Worth 163.5 Billion KRW

알파경제2024.12.17 01:03
  • AI챗으로 요약

AI요약

기사 제목과 본문 내용을 자동 요약한 내용입니다. 전체 내용을 이해하기 위해서는 기사 본문 전체를 확인하는 것이 더 좋습니다.

AI챗이 열심히 분석 중입니다.잠시만 기다려주세요.

AI챗 바로가기
Mezzion Pharma Acquires Additional Shares in U.S. Subsidiary Worth 163.5 Billion KRW이미지 크게 보기


[Alpha Biz= Reporter Kim Jisun] Mezzion Pharma announced on the 16th that it would acquire an additional 158 shares of its U.S. subsidiary, Mezzion Pharmaceuticals, for approximately 163.5 billion KRW. Mezzion Pharmaceuticals, a subsidiary of Mezzion, was established in the U.S. for the purpose of developing and selling new drugs.

Even after the acquisition, Mezzion's ownership stake remains 100%. The acquisition method involves converting a loan receivable into capital, and the purpose of the acquisition is to improve financial stability.

관련기사

▶ Doosan Bobcat Announces Industry-Leading Shareholder Return Plan with 200 Billion KRW Buyback

▶ Hanwha Aerospace Appoints Michael Coulter to Strengthen Global Defense Business

▶ National Tax Service Launches Tax Audit on SK Telecom

▶ U.S. DOE Grants Final Approval for $13.8 Trillion Loan to SK On-Ford Joint Venture, BlueOval SK

▶ [경제용어 나들이] '글로벌 가치 사슬'이 뭘까요? : 경제용어사전｜알파경제TV

/ 알파경제 Kim Jisun Reporter

현대해상 KB손해보험 DB손해보험
운전자보험 11번가 AXA손해보험